MaxCyte will announce Q2 2025 financial results on August 6, followed by a conference call.
Quiver AI Summary
MaxCyte, Inc., a company specializing in cell engineering to facilitate the development of cell therapeutics, announced that it will release its financial results for the second quarter of 2025 on August 6, 2025, after the market closes. Following the release, management will host a conference call at 4:30 p.m. Eastern Time to discuss these results, and interested investors must register in advance to participate. The event will also be available as a live and archived webcast on the MaxCyte website. The company emphasizes its commitment to advancing cell therapies through its innovative technologies and extensive expertise in the field.
Potential Positives
- MaxCyte is positioned to demonstrate its financial performance for Q2 2025, which could indicate growth and stability to investors.
- The scheduled conference call provides a platform for management to directly engage with investors and stakeholders, enhancing transparency and communication.
- MaxCyte’s 25-year history in advancing cell engineering underscores its experience and credibility in the biotechnology sector, potentially attracting interest from partners and investors.
- The emphasis on next-generation cell therapeutics and innovative technologies, such as Flow Electroporation® and SeQure DX™, highlights the company's focus on cutting-edge solutions in healthcare, indicating potential market leadership.
Potential Negatives
- Absence of financial performance data in the release may signal financial uncertainty or issues that the company is not ready to disclose.
- Requiring investors to register online for theearnings callcould limit participation and transparency for shareholders.
- The scheduledearnings callfor August 6th means stakeholders will have to wait several weeks for information about the quarter's financial performance, which could create speculation or concern about the company's current status.
FAQ
When will MaxCyte release its Q2 2025 financial results?
MaxCyte will release its Q2 2025 financial results on August 6, 2025, after the U.S. market close.
How can I listen to the MaxCyteearnings conference call
Interested investors must register online to listen to the conference call at 4:30 p.m. Eastern Time on August 6, 2025.
Where can I find the webcast of theearnings call
A live and archived webcast of theearnings callwill be available in the “Events” section of the MaxCyte website.
What technologies does MaxCyte specialize in?
MaxCyte specializes in cell engineering technologies, including Flow Electroporation® and SeQure DX™ gene editing services.
How long has MaxCyte been in the cell engineering industry?
MaxCyte has over 25 years of experience in advancing cell engineering and developing next-generation cell therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MXCT Insider Trading Activity
$MXCT insiders have traded $MXCT stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $MXCT stock by insiders over the last 6 months:
- DOUGLAS J SWIRSKY (CHIEF FINANCIAL OFFICER) sold 6,939 shares for an estimated $22,061
- DAVID I. SANDOVAL (GENERAL COUNSEL) has made 0 purchases and 2 sales selling 4,819 shares for an estimated $21,393.
- JOHN JOSEPH JOHNSTON sold 3,000 shares for an estimated $13,934
- ALI SOLEYMANNEZHAD (Chief Commercial Officer) sold 1,211 shares for an estimated $3,850
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MXCT Hedge Fund Activity
We have seen 48 institutional investors add shares of $MXCT stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 2,592,546 shares (+58.8%) to their portfolio in Q1 2025, for an estimated $7,077,650
- MILLENNIUM MANAGEMENT LLC removed 1,362,542 shares (-49.7%) from their portfolio in Q1 2025, for an estimated $3,719,739
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,135,613 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,100,223
- GAGNON ADVISORS, LLC added 934,196 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,550,355
- CHEVY CHASE TRUST HOLDINGS, LLC added 890,353 shares (+66.5%) to their portfolio in Q1 2025, for an estimated $2,430,663
- GAGNON SECURITIES LLC added 850,992 shares (+431.3%) to their portfolio in Q1 2025, for an estimated $2,323,208
- CADIAN CAPITAL MANAGEMENT, LP added 683,303 shares (+7.3%) to their portfolio in Q1 2025, for an estimated $1,865,417
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MXCT Analyst Ratings
Wall Street analysts have issued reports on $MXCT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 03/12/2025
To track analyst ratings and price targets for $MXCT, check out Quiver Quantitative's $MXCT forecast page.
Full Release
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6
th
, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to
register online
. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/
.
About MaxCyte
At MaxCyte
®
, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation
®
technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at
maxcyte.com
and follow us on
X
and
LinkedIn
.
Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
